Biomed. Papers 148(1), 3-10 (2004) | DOI: 10.5507/bp.2004.001

AROMATIC HYDROCARBON RECEPTOR STATUS IN THE METABOLISM OF XENOBIOTICS UNDER NORMAL AND PATHOPHYSIOLOGICAL CONDITIONS

Radim Vrzal, Jitka Ulrichová, Zdeněk Dvořák
Institute of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacký University, Olomouc, Hněvotínská 3, 775 15, Czech Republic

The aryl hydrocarbon receptor (AhR), a cytosolic protein belonging to the family of nuclear receptors, controls transcription of a wide range of structurally unrelated genes. To date, the most potent AhR ligand is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Exposure to TCDD leads to a number of toxic effects, in particular to tumor promotion and immunosuppression. The function of AhR in cells and living organisms therefore seems to be of paramount importance. Its absence in AhR null mice, results in severe phenotypic abnormalities, such as liver half size with fibrosis, accumulation of retinoic acid and immune system insufficiency. An important role of AhR inheres in its transcriptional control of several biotransformation enzymes (CYP1A1/2,1B1). Hence AhR is the crucial factor in the regulation of xenobiotic metabolism. Under pathophysiological conditions, such as inflammation, the level and activity of the AhR target gene CYP1A is decreased. Thus it is likely, that mediators and/or products of inflammation affect AhR function. This review deals with the role of AhR in xenobiotic metabolism under normal and pathophysiological conditions, with respect to inflammation in particular.

Keywords: AhR receptor, Regulation, Xenobiotics, Metabolism, Inflammation

Received: April 10, 2004; Accepted: May 22, 2004; Published: July 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Vrzal, R., Ulrichová, J., & Dvořák, Z. (2004). AROMATIC HYDROCARBON RECEPTOR STATUS IN THE METABOLISM OF XENOBIOTICS UNDER NORMAL AND PATHOPHYSIOLOGICAL CONDITIONS. Biomedical papers148(1), 3-10. doi: 10.5507/bp.2004.001
Download citation

References

  1. Frye RF, Schneider VM, Frye CS, Feldman AM. (2002) Plasma Levels of TNF- and IL-6 are Inversely Related to Cytochrome P450-dependent Drug Metabolism in Patients With Congestive Heart Failure. J Card Fail 8, 315-9. Go to original source... Go to PubMed...
  2. Lewis DFV, Watson E, Lake BG. (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res 410, 245-70. Go to original source... Go to PubMed...
  3. Rogers JF, Nafziger AN, Bertino JS. (2002) Pharmacogenetics Aff ects Dosing, Effi cacy, and Toxicity of Cytochrome P450-Metabolized Drugs. Am J Med 113, 746-50. Go to original source... Go to PubMed...
  4. Gonzales FJ. (1998) The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. Toxicol Lett 102-103, 161-6 Go to original source... Go to PubMed...
  5. Ioannides C. Enzyme systems that metabolize drugs and other xenobiotics. Chichester: John Wiley and Sons Ltd., 2001. Go to original source...
  6. Leeder JS. (2001) Ontogeny of Drug-Metabolizing Enzymes and Its Infl uence on the Pathogenesis of Adverse Drug Reactions in Children. Curr Ther Res Clin Exp 62, 900-12. Go to original source...
  7. McLaughlin L, Burchell B, Pritchard M, Wolf CR, Friedberg T. (1999) Treatment of mammalian cells with the endoplasmic reticulum-proliferator compactin strongly induces recombinant and endogenous xenobiotic metabolizing enzymes and 3-hydroxy- 3-methylglutaryl-CoA reductase in vitro. J Cell Sci 112, 515-23. Go to original source... Go to PubMed...
  8. Ito S, Alcorn J. (2003) Xenobiotic transporter expression and function in the human mammary gland. Adv Drug Deliv Rev 55, 653-65. Go to original source... Go to PubMed...
  9. Lin JH, Yamazaki M. (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42, 59 -98 Go to original source... Go to PubMed...
  10. Hagenbuch B, Meier PJ. (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609, 1-18. Go to original source... Go to PubMed...
  11. Mikamo E, Harada S, Nishikawa JI, Nishihara T. (2003) Endocrine disruptors induce cytochrome P450 by aff ecting transcriptional regulation via pregnane X receptor, Toxicol Appl Pharmacol 193, 66-72. Go to original source... Go to PubMed...
  12. Faber KN, Muller M, Jansen PLM. (2003) Drug transport proteins in the liver. Adv Drug Deliv Rev 55, 107-24. Go to original source... Go to PubMed...
  13. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. (2003) The expression of CYP 2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619, 234-53. Go to original source... Go to PubMed...
  14. Honkakoski P, Negishi M. (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347, 321-37. Go to original source... Go to PubMed...
  15. Pascussi JM, Dvořák Z, Gerbal-Chaloin S, Assenat E, Maurel P, Vilarem MJ. (2003) Pathophysiological factors aff ecting CAR gene expression. Drug Met Rev 35, 255-68. Go to original source... Go to PubMed...
  16. Mimuraa J, Kuriyama YF. (2003) Functional role of AhR in the expression of toxic eff ects by TCDD. Biochim Biophys Acta 1619, 263-8. Go to original source... Go to PubMed...
  17. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. (2000) Role of the Aromatic Hydrocarbon Receptor and [Ah] Gene Battery in the Oxidative Stress Response, Cell Cycle Control, and Apoptosis. Biochem Pharmacol 59, 65-85. Go to original source... Go to PubMed...
  18. Hahn ME. (2002) Aryl hydrocarbon receptors: diversity and evolution. Chem Biol Interact 141, 131-60. Go to original source... Go to PubMed...
  19. Harper PA, Wong JMY, Lam MSM, Okey AB. (2002) Polymorphisms in the human AH receptor. Chem Biol Interact 141, 161-87. Go to original source... Go to PubMed...
  20. Barouki R, Morel Y. (2001) Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications. Biochem Pharmacol 61, 511-6. Go to original source... Go to PubMed...
  21. Matsumura F. (2003) On the signifi cance of the role of cellular stress response reactions in the toxic actions of dioxin. Biochem Pharmacol 66, 527-40. Go to original source... Go to PubMed...
  22. Safe S. (2001) Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120, 1-7. Go to original source... Go to PubMed...
  23. Pollenz RS. (2002) The mechanism of AH receptor protein downregulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem Biol Interact 141, 41-61. Go to original source... Go to PubMed...
  24. Denison MS, Pandini A, Nagy SR, Baldwin EP, Bonati L. (2002) Ligand binding and activation of the Ah receptor. Chem Biol Interact 141, 3-24. Go to original source... Go to PubMed...
  25. Hahn ME. (1998) The aryl hydrocarbon receptor: A comparative perspective. Comp Biochem Physiol C 121, 23-53. Go to original source... Go to PubMed...
  26. Hodek P, Trefi l P, Stiborova M. (2002) Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 139, 1-21. Go to original source... Go to PubMed...
  27. Delescluse C, Lemaire G, de Sousa G, Rahmani R. (2000) Is CYP1A1 induction always related to AHR signaling pathway? Toxicology 153, 73-82. Go to original source... Go to PubMed...
  28. Barouki R. Signalisation par le récepteur AhR: role de diff érents ligands et interaction avec le stress oxydant. In abstract book from 8th Annual Meeting of the Societe Francaise de Pharmacologie. Strasbourg, 26-28 April 2004.
  29. Villard PH, Fallone F, Sérée E, Rimet O, Bourgarel-Rey V, Fouchier F, Barra Y, Durand A, Lacarelle B. (2004) Repressive eff ect of retinoic acid toward the Ah receptor CYP1A1 induction pathway. Fundam Clin Pharmacol 18, p. 219. 8th Annual Meeting of the Societe Francaise de Pharmacologie, Strasbourg, 26-28 April 2004.
  30. Ehrmann J Jr., Vavrusova N., Collan Y, Kolar Z. (2002) Peroxisome proliferator-activated receptors (PPARs) in health and disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 146, 11-4. Go to original source... Go to PubMed...
  31. Puga A, Xia Y, Elferink C. (2002) Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem Biol Interact 141, 117-30. Go to original source... Go to PubMed...
  32. Nebert DW, Roe AL. (2001) Ethnic and genetic diff erences in metabolism genes and risk of toxicity and cancer. Sci Total Environ 274, 93-102. Go to original source... Go to PubMed...
  33. Vineis P. (2002) The relationship between polymorphisms of xe no biotic metabolizing enzymes and susceptibility to cancer. Toxicology 181-182, 457-62. Go to original source... Go to PubMed...
  34. Crespi ChL, Miller VP. (1999) The use of heterologously expressed drug metabolizing enzymes state of the art and prospects for the future. Pharmacol Ther 84, 121-31. Go to original source... Go to PubMed...
  35. Czekaj P. (2000) Phenobarbital-induced expression of cytochrome P450 genes. Acta Biochim Pol 47, 1093-105. Go to original source... Go to PubMed...
  36. Gilmore J, Rotondo F, Pelletier AM, LaMarre J, Alaoui-Jamali M, Kirby GM. (2001) Identifi cation of a 43-kDa protein in human liver cytosol that binds to the 39-untranslated region of CYP2A6 mRNA. Biochem Pharmacol 62, 669-78 Go to original source... Go to PubMed...
  37. Haack MJ, Bak MLFJ, Beurskens R, Maes M, Stolk LML, Delespaul PAEG. (2003) Toxic rise of clozapine plasma concentrations in relation to infl ammation. Eur Neuropsychopharmacol 13, 381-85. Go to original source... Go to PubMed...
  38. Renton KW. (2001) Alteration of drug biotransformation and elimination during infection and inf lammation. Pharmacol Ther 92, 147-63. Go to original source... Go to PubMed...
  39. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, Vilarem M-J. (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274, 707-13. Go to original source... Go to PubMed...
  40. Tian Y, Rabson AB, Gallo MA. (2002) Ah receptor and NF-B interactions: mechanisms and physiological implications. Chem Biol Interact 141, 97-115. Go to original source... Go to PubMed...
  41. Gilmore WJ, Hartmann G, Miller MP, Marriott J, Kirby GM. (2003) Eff ects of lipopolysaccharide-stimulated infl ammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology 184, 211-26. Go to original source... Go to PubMed...
  42. Masubuchi Y, Horie T. (2003) Resistance to indomethacin-induced down-regulation of hepatic cytochrome P450 enzymes in the mice with non-functional Toll-like receptor 4. J Hepatol 39, 349-56. Go to original source... Go to PubMed...
  43. Stadler J, Schmalix WA, Dochmer J. (1995) Inhibition of biotransformation by nitric oxide (NO) overproduction and toxic consequences. Toxicol Lett 82/83, 215-9. Go to original source... Go to PubMed...